Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate

@article{Henriksson1988CardiovascularFO,
  title={Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate},
  author={Peter Henriksson and Ambj{\"o}rn Eriksson and Reinhard Stege and Lars G. Collste and {\AA}ke Pousette and B O VON Schoultz and Kjell Carlstr{\"o}m},
  journal={The Prostate},
  year={1988},
  volume={13}
}
Thirty‐eight patients with cancer of the prostate were treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections–160 mg, 240 mg, and 320 mg—in this nonrandomized study. In contrast to studies with oral estrogens, there have been no cardiovascular complications at a mean follow‐up of 12.9 ± 0.7 months (SEM). Twenty‐nine of the 38 patients (76%) have responded to therapy. 

Cardiovascular and all‐cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population

  • J. Aro
  • Medicine
    The Prostate
  • 1991
It is concluded that intramuscular PEP monotherapy is associated with low cardiovascular mortality and with an all‐cause and prostatic cancer mortality equal to orchiectomy.

Cost Comparison of Parenteral Estrogen and Conventional Hormonal Treatment in Patients With Prostatic Cancer

  • P. HenrikssonR. Stege
  • Medicine, Biology
    International Journal of Technology Assessment in Health Care
  • 1991
The initial cost of orchidectomy as compared to nonoral estrogen treatment was shown not to be balanced within the expected survival time of patients with advanced prostatic cancer, and surgical castration causes psychological trauma to the patient.

Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

High-dose polyestradiol phosphate (PEP) has an equal anticancer efficacy to CAD and does not increase cardiovascular mortality, and is considerably cheaper than CAD.

Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen

The present pilot study tested the clinical performance of a new pharmacokinetically guided dosing regimen of parenteral estrogen in patients with advanced prostatic carcinoma. The aim was to

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

PEP has an anticancer efficacy equal to CAD and does not increase cardiovascular mortality in metastasized patients, but carries a significant risk of non-fatal cardiovascular events, which should be balanced against the skeletal complications in the CAD group.

Estrogen in Patients with Prostatic Cancer

SummaryEstrogen therapy of patients with prostatic carcinoma appears to be at least as effective in antitumour activity as surgical castration; the recent therapeutic alternative of gonadorelin

Parenteral oestrogens for prostate cancer: a systematic review of clinical effectiveness and dose response

The great majority of evidence was concerned with i.m. PEP, but was largely of poor quality or was poorly reported, and the largest and highest quality trials included in the review do not provide long-term survival data.

Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy

Parenteral estrogen therapy has the advantage of giving protection against the effects of andropause, which are induced by conventional androgen suppression and include osteoporotic fracture, hot flashes, asthenia and cognitive dysfunction.

Diethylstilboestrol for the treatment of prostate cancer: past, present and future

The most relevant clinical studies using DES in castration-refractory prostate cancer (CRPC) were identified from the literature and the efficacy of oestrogen therapy in CRPC is highlighted.

References

SHOWING 1-8 OF 8 REFERENCES

Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.

The substantially increased risk of cardiovascular complications in patients given oestrogen for prostatic cancer warrants careful consideration when choosing treatment for this disorder.

STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND

Evidence is presented that significant improvement often occurs in the clinical condition of patients with far advanced cancer of the prostate after they have been subjected to castration and this work provides a new concept of prostatic carcinoma.

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate

It is demonstrated that a marked rise in acid phosphatase in serum is associated with the appearance or spread of roentgenologically demonstrable skeletal metastases and implies dissemination of the primary tumor and thus is of unfavorable prognostic significance.

A NEW AND SENSITIVE METHOD FOR QUANTIFYING AND COMPARING THE BIOLOGICAL POTENCY OF VARIOUS ESTROGENS IN MAN

The serum level of an estrogen‐inducible plasma protein was followed by a radioimmunoassay in groups of women during treatment with various estrogens and an estrogen index was constructed.

Carcinoma of the prostate: treatment comparisons.